Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.34 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.33 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | STAT3 | P40763 | 1/20 | 0.31 |
| ▸ | SELL | P14151 | 6/20 | 0.31 |
| ▸ | SELP | P16109 | 6/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26824204 | 1.00 | L3MBTL1 (0.36) | L3MBTL1FUCA1AMY1ASYNJ2NR1H3 | |
| SCHEMBL11277134 | 1.00 | L3MBTL1 (0.36) | L3MBTL1FUCA1AMY1ASYNJ2NR1H3 | |
| SCHEMBL26759947 | 1.00 | L3MBTL1 (0.36) | L3MBTL1FUCA1AMY1ASYNJ2NR1H3 | |
| SCHEMBL2046273 | 1.00 | L3MBTL1 (0.36) | L3MBTL1FUCA1AMY1ASYNJ2NR1H3 | |
| SCHEMBL5670720 | 1.00 | L3MBTL1 (0.36) | L3MBTL1FUCA1AMY1ASYNJ2NR1H3 | |
| SCHEMBL18305015 | 1.00 | L3MBTL1 (0.36) | L3MBTL1FUCA1AMY1ASYNJ2NR1H3 | |
| SCHEMBL13079298 | 1.00 | L3MBTL1 (0.36) | L3MBTL1FUCA1AMY1ASYNJ2NR1H3 | |
| SCHEMBL1119069 | 1.00 | L3MBTL1 (0.36) | L3MBTL1FUCA1AMY1ASYNJ2NR1H3 | |
| SCHEMBL18940518 | 1.00 | L3MBTL1 (0.36) | L3MBTL1FUCA1AMY1ASYNJ2NR1H3 | |
| SCHEMBL17773549 | 0.87 | FUCA1 (0.33) | FUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002423-A1 | PROTECTED TETRASACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE AS TRANSGLUCOSYLASE ACCEPTOR SUBSTRATES IN THE CHEMO-ENZYMATIC SYNTHESIS OF SHIGELLA FLEXNERI SPECIFIC OLIGOSACCHARIDES | PASTEUR INSTITUT (FR) | 2024-01-04 | — | — | US | disclosed |
| US-11834468-B2 | Protected tetrasaccharides, their process of preparation and their use as transglucosylase acceptor substrates in the chemo-enzymatic synthesis of Shigella flexneri specific oligosaccharides | INSTITUT PASTEUR (FR) | 2023-12-05 | — | — | US | disclosed |
| US-20200165285-A1 | PROTECTED TETRASACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE AS TRANSGLUCOSYLASE ACCEPTOR SUBSTRATES IN THE CHEMO-ENZYMATIC SYNTHESIS OF SHIGELLA FLEXNERI SPECIFIC OLIGOSACCHARIDES | INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (FR) | 2020-05-28 | — | — | US | disclosed |
| EP-3649141-A1 | PROTECTED TETRASACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE AS TRANSGLUCOSYLASE ACCEPTOR SUBSTRATES IN THE CHEMO-ENZYMATIC SYNTHESIS OF SHIGELLA FLEXNERI SPECIFIC OLIGOSACCHARIDES | Institut Pasteur (FR) | 2020-05-13 | — | — | EP | disclosed |
| CN-111032671-A | Protected tetrasaccharide, method for its preparation, and use thereof as a substrate for the transglucosylase receptor in the chemoenzymatic synthesis of shigella flexneri-specific oligosaccharides | 巴斯德研究所 | 2020-04-17 | — | — | CN | disclosed |
| WO-2019007999-A1 | PROTECTED TETRASACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE AS TRANSGLUCOSYLASE ACCEPTOR SUBSTRATES IN THE CHEMO-ENZYMATIC SYNTHESIS OF SHIGELLA FLEXNERI SPECIFIC OLIGOSACCHARIDES | INSTITUT PASTEUR (FR) | 2019-01-10 | — | — | WO | disclosed |
| US-9446109-B2 | Glycoconjugates and their use as potential vaccines against infection by Shigella flexneri | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-09-20 | — | — | US | disclosed |
| US-9163049-B2 | Medicament comprising a reducing alkyl-sugar monomer for the treatment of inflammatory disorders | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2015-10-20 | — | — | US | disclosed |
| EP-2369345-B1 | Glycoconjugates and their use as potential vaccines against infection by shigella flexneri | PASTEUR INSTITUT (FR) | 2014-10-01 | — | — | EP | disclosed |
| US-20140161793-A2 | GLYCOCONJUGATES AND THEIR USE AS POTENTIAL VACCINES AGAINST INFECTION BY SHIGELLA FLEXNERI | INSERM (FR) | 2014-06-12 | — | — | US | disclosed |
| EP-2266580-A1 | Medicament comprising a reducing alkyl-sugar monomer for the treatment of inflammatory disorders | Pierre Fabre Dermo-Cosmétique (FR) | 2010-12-29 | — | — | EP | disclosed |
| US-20100069311-A1 | MEDICAMENT COMPRISING A REDUCING ALKYL-SUGAR MONOMER FOR THE TREATMENT OF INFLAMMATORY DISORDERS | HOULMONT JEAN-PHILIPPE | 2010-03-18 | — | — | US | disclosed |
| US-7666847-B2 | Medicament comprising a reducing alkyl-sugar monomer for the treatment of inflammatory disorders | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2010-02-23 | — | — | US | disclosed |
| WO-2005003775-A9 | GLYCOCONJUGATES AND THEIR USE AS POTENTIAL VACCINES AGAINST INFECTION BY SHIGELLA FLEXNERI | PASTEUR INSTITUT (FR) | 2008-11-06 | — | — | WO | disclosed |
| US-20080112951-A1 | Glycoconjugates and Their Use as Potential Vaccines Against Infection by Shigella Flexneri | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2008-05-15 | — | — | US | disclosed |
| US-20070134187-A1 | Medicament comprising a reducing alkyl-sugar monomer for the treatment of inflammatory disorders | CENTRE NATIONAL DE LA RECHESRCHE SCIENTIFIQUE (CNRS) (FR) | 2007-06-14 | — | — | US | disclosed |
| EP-1682158-A1 | MEDICAMENT COMPRISING A REDUCING ALKYL-SUGAR MONOMER FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Pierre Fabre Dermo-Cosmetique (FR) | 2006-07-26 | — | — | EP | disclosed |
| EP-1642132-A2 | GLYCOCONJUGATES AND THEIR USE AS POTENTIAL VACCINES AGAINST INFECTION BY SHIGELLA FLEXNERI | INSTITUT PASTEUR (FR) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005041983-A1 | MEDICAMENT COMPRISING A REDUCING ALKYL-SUGAR MONOMER FOR THE TREATMENT OF INFLAMMATORY DISORDERS | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005003775-A2 | GLYCOCONJUGATES AND THEIR USE AS POTENTIAL VACCINES AGAINST INFECTION BY SHIGELLA FLEXNERI | INSTITUT PASTEUR (FR) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834468-B2 | Protected tetrasaccharides, their process of preparation and their use as transglucosylase acceptor substrates in the chemo-enzymatic synthesis of Shigella flexneri specific oligosaccharides | SI, GALE, FUT5 | L3MBTL1 4132/4885FUCA1 11/4885AMY1A 106/4885 |
| US-20200165285-A1 | PROTECTED TETRASACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE AS TRANSGLUCOSYLASE ACCEPTOR SUBSTRATES IN THE CHEMO-ENZYMATIC SYNTHESIS OF SHIGELLA FLEXNERI SPECIFIC OLIGOSACCHARIDES | SI, GALE, FUT5 | L3MBTL1 4132/4885FUCA1 11/4885AMY1A 106/4885 |
| US-20140161793-A2 | GLYCOCONJUGATES AND THEIR USE AS POTENTIAL VACCINES AGAINST INFECTION BY SHIGELLA FLEXNERI | FUT6, GNE, STT3B | L3MBTL1 2092/4885FUCA1 57/4885AMY1A 2281/4885 |
| US-20100069311-A1 | MEDICAMENT COMPRISING A REDUCING ALKYL-SUGAR MONOMER FOR THE TREATMENT OF INFLAMMATORY DISORDERS | UGCG, UGGT1, TLR6 | L3MBTL1 2927/4885FUCA1 80/4885AMY1A 279/4885 |
| US-20240002423-A1 | PROTECTED TETRASACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE AS TRANSGLUCOSYLASE ACCEPTOR SUBSTRATES IN THE CHEMO-ENZYMATIC SYNTHESIS OF SHIGELLA FLEXNERI SPECIFIC OLIGOSACCHARIDES | SI, GALE, FUT5 | L3MBTL1 4132/4885FUCA1 11/4885AMY1A 106/4885 |
| US-20070134187-A1 | Medicament comprising a reducing alkyl-sugar monomer for the treatment of inflammatory disorders | UGCG, TLR6, CD68 | L3MBTL1 4208/4885FUCA1 41/4885AMY1A 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.